Status:
COMPLETED
The Consistency of Drug Screening in Vitro and Neoadjuvant Chemotherapy Results in Breast Cancer Patients
Lead Sponsor:
Peking University People's Hospital
Collaborating Sponsors:
Peking University
Conditions:
Breast Cancer
Drug Effect
Eligibility:
FEMALE
18-70 years
Brief Summary
Neoadjuvant chemotherapy for breast cancer could make unresectable breast cancer be resectable and improve breast conservation rate. Patients with triple negative or Her2 enriched subtype who achieved...
Detailed Description
Neoadjuvant chemotherapy for breast cancer could make unresectable breast cancer be resectable and improve breast conservation rate. Patients with triple negative or Her2 enriched subtype who achieved...
Eligibility Criteria
Inclusion
- invasive breast cancer candidates for neoadjuvant chemotherapy agreed to participate in this observative experiments could receive operation normal liver and renal function
Exclusion
- inflammatory breast cancer recurrent breast cancer
Key Trial Info
Start Date :
April 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2019
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT04131881
Start Date
April 1 2017
End Date
September 1 2019
Last Update
October 18 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University People'S Hospital
Beijing, Beijing Municipality, China, 100044